Asthma and Severe Asthma Epidemiology Analysis and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3995

Asthma and Severe Asthma Report Overview

In the 8MM, there were 56,552,679 12-month diagnosed prevalent cases of asthma in 2023. The diagnosed prevalent cases will register an AGR of less than 1% during 2023-2033. Asthma is a common lung condition characterized by the narrowing and swelling of the lungs’ airways and the production of excess mucus. Common asthma symptoms include wheezing, breathlessness, chest tightness, and coughing at night or early in the morning.

Asthma and Severe Asthma Market Outlook, 2023-2033 (Diagnosed Prevalent Cases)

Asthma and Severe Asthma Market Outlook, 2023-2033 (Diagnosed Prevalent Cases)

Buy the Full Report for More Insights into the Asthma and Severe Asthma Market Forecast

Download a Free Report Sample

The asthma and severe asthma market research report provides an overview of the risk factors, comorbidities, and global trends of asthma and severe asthma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report includes a 10-year epidemiological forecast for the 12-month and lifetime diagnosed prevalent cases of asthma and severe asthma, segmented by age and sex.

Market Size (2023) 56,552,679 Cases
AGR (2023-2033) <1%
Forecast Period 2023-2033
Key Countries ·       The US

·       France

·       Germany

·       Spain

·       Italy

·       The UK

·       Japan

·       China

Key Sex Segments ·       Men

·       Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Asthma and Severe Asthma Market Segmentation by Country

The key countries across the 8MM are the US, France, Germany, Spain, Italy, the UK, Japan, and China. In 2023, the US accounted for the highest number of diagnosed prevalent cases of asthma and severe asthma in the 8MM. Any change in the diagnosed prevalent cases of asthma is attributable to changing population demographics and changing diagnosed prevalence rates based on trend analysis in the 8MM.

Asthma and Severe Asthma Market Analysis by Country, 2023 (%)

Asthma and Severe Asthma Market Analysis by Country, 2023 (%)

Buy the Full Report for More Country Insights into the Asthma and Severe Asthma Market
Download a Free Report Sample

Asthma and Severe Asthma Market Segmentation by Sex Type

Based on sex, the market can be segmented into men and women. In 2023, the number of 12-month diagnosed prevalent cases of asthma was higher in women than in men in the 8MM combined. Japan had the smallest variation in the number of diagnosed prevalent cases between men and women.

Asthma and Severe Asthma Market Analysis by Sex, 2023 (%)

Asthma and Severe Asthma Market Analysis by Sex, 2023 (%)

Buy the Full Report for More Sex Type Insights into the Asthma and Severe Asthma Market

Download a Free Report Sample

Segments Covered in the Report

Asthma and Severe Asthma Country Outlook (Diagnosed Prevalent Cases)

  • The US
  • France
  • Germany
  • Spain
  • Italy
  • The UK
  • Japan
  • China

Asthma and Severe Asthma Sex Outlook (Diagnosed Prevalent Cases)

  • Men
  • Women

Scope

The Asthma and Severe Asthma Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of asthma and severe asthma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

The report includes a 10-year epidemiological forecast for the 12-month and lifetime diagnosed prevalent cases of asthma and severe asthma, segmented by age (0 years up to 80 years older by 10-year age groups) and sex. The 12-month and lifetime diagnosed prevalent cases of severe asthma are further segmented by inflammatory subtype (atopic or allergic asthma, eosinophilic or neutrophilic).

Reasons to Buy

The asthma and severe asthma epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global asthma and severe asthma markets.
  • Quantify patient populations in the global asthma and severe asthma markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for asthma and severe asthma therapeutics in each of the market covered.
  • Understand the magnitude of the asthma and severe asthma population by age and sex and the severe asthma population by inflammatory subtype.

Table of Contents

  • 1 Asthma and Severe Asthma: Executive Summary

    • 1.1 Catalyst
    • 1.2 Related reports
    • 1.3 Upcoming reports

  • 2 Epidemiology

    • 2.1 Disease background
    • 2.2 Risk factors and comorbidities.
    • 2.3 Global and historical trends
    • 2.4 8MM forecast methodology.

      • 2.4.1 Sources
      • 2.4.2 Forecast assumptions and methods.
      • 2.4.3 Forecast assumptions and methods: 12-month diagnosed prevalent cases of asthma – 8MM
      • 2.4.4 Forecast assumptions and methods: lifetime diagnosed prevalent cases of asthma – 8MM.
      • 2.4.5 Forecast assumptions and methods: 12-month diagnosed prevalent cases of severe asthma
      • 2.4.6 Forecast assumptions and methods: lifetime diagnosed prevalent cases of severe asthma
      • 2.4.7 Forecast assumptions and methods: 12-month diagnosed prevalent cases of severe asthma by inflammatory subtypes.
      • 2.4.8 Forecast assumptions and methods: lifetime diagnosed prevalent cases of severe asthma by inflammatory subtypes.

    • 2.5 Epidemiological forecast for asthma and severe asthma (2023–33)

      • 2.5.1 12-month diagnosed prevalent cases of asthma
      • 2.5.2 Age-specific 12-month diagnosed prevalent cases of asthma. 2.5.3 Sex-specific 12-month diagnosed prevalent cases of asthma
      • 2.5.4 Lifetime diagnosed prevalent cases of asthma
      • 2.5.5 Age-specific lifetime diagnosed prevalent cases of asthma
      • 2.5.6 Sex-specific lifetime diagnosed prevalent cases of asthma
      • 2.5.7 12-month diagnosed prevalent cases of severe asthma
      • 2.5.8 Age-specific 12-month diagnosed prevalent cases of severe asthma
      • 2.5.9 Sex-specific 12-month diagnosed prevalent cases of severe asthma
      • 2.5.10 Lifetime diagnosed prevalent cases of severe asthma
      • 2.5.11 Age-specific lifetime diagnosed prevalent cases of severe asthma
      • 2.5.12 Sex-specific lifetime diagnosed prevalent cases of severe asthma
      • 2.5.13 12-month diagnosed prevalence of severe asthma by inflammatory subtypes
      • 2.5.14 Lifetime diagnosed prevalence of severe asthma by inflammatory subtypes

    • 2.6 Discussion

      • 2.6.1 Epidemiological forecast insight
      • 2.6.2 COVID-19 impact
      • 2.6.3 Limitations of the analysis
      • 2.6.4 Strengths of the analysis

  • 3 Appendix

    • 3.1 Bibliography
    • 3.2 Primary research – high prescriber survey
    • 3.3 About the Authors

      • 3.3.1 Epidemiologist
      • 3.3.2 Reviewers
      • 3.3.3 Vice President of Disease Analysis and Intelligence
      • 3.3.4 Global Head and EVP of Healthcare Operations and Strategy

  • 4 Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Global Initiative for Asthma Treatment Stages

Table 4: Risk factors and comorbidities for severe asthma

Table 5: High-prescribing physicians surveyed, by country

Figures

Figure 1: 8MM, 12-month diagnosed prevalent cases of asthma, both sexes, N, all ages, 2023 and 2033

Figure 2: 8MM, lifetime diagnosed prevalent cases of asthma, both sexes, N, all ages, 2023 and 2033

Figure 3: 8MM, 12-month diagnosed prevalent cases of severe asthma, both sexes, N, all ages, 2023 and 2033

Figure 4: 8MM, lifetime diagnosed prevalent cases of severe asthma, both sexes, N, all ages, 2023 and 2033

Figure 5: 8MM, 12-month diagnosed prevalence of asthma, both sexes, %, all ages, 2013–33

Figure 6: 8MM, lifetime diagnosed prevalence of asthma, both sexes, %, all ages, 2013–33

Figure 7: 8MM, 12-month diagnosed prevalence of severe asthma, both sexes, %, all ages, 2013–33

Figure 8: 8MM, lifetime diagnosed prevalence of severe asthma, both sexes, %, all ages, 2013–33

Figure 9: 8MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of asthma

Figure 10: 8MM, sources used to forecast the lifetime diagnosed prevalent cases of asthma

Figure 11: 8MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of severe asthma

Figure 12: 8MM, sources used to forecast the lifetime diagnosed prevalent cases of severe asthma

Figure 13: 8MM, 12-month diagnosed prevalent cases of asthma, N, both sexes, all ages, 2023

Figure 14: 8MM, 12-month diagnosed prevalent cases of asthma by age, N, both sexes, 2023

Figure 15: 8MM, 12-month diagnosed prevalent cases of asthma by sex, N, all ages, 2023

Figure 16: 8MM, lifetime diagnosed prevalent cases of asthma, N, both sexes, all ages, 2023

Figure 17: 8MM, lifetime diagnosed prevalent cases of asthma by age, N, both sexes, 2023

Figure 18: 8MM, lifetime diagnosed prevalent cases of asthma by sex, N, all ages, 2023

Figure 19: 8MM, 12-month diagnosed prevalent cases of severe asthma, N, both sexes, all ages, 2023

Figure 20: 8MM, 12-month diagnosed prevalent cases of severe asthma by age, N, both sexes, 2023

Figure 21: 8MM, 12-month diagnosed prevalent cases of asthma by sex, N, all ages, 2023

Figure 22: 8MM, lifetime diagnosed prevalent cases of severe asthma, N, both sexes, all ages, 2023

Figure 23: 8MM, lifetime diagnosed prevalent cases of severe asthma by age, N, both sexes, 2023

Figure 24: 8MM, lifetime diagnosed prevalent cases of severe asthma by sex, N, all ages, 2023

Figure 25: 8MM, 12-month diagnosed prevalent cases of severe asthma by inflammatory subtypes, N, both sexes, ages ≥20 years, 2023

Figure 26: 8MM, lifetime diagnosed prevalent cases of severe asthma by inflammatory subtypes, N, both sexes, ages ≥20 years, 2023

Frequently asked questions

Asthma and Severe Asthma Epidemiology Analysis and Forecast to 2033 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Asthma and Severe Asthma Epidemiology Analysis and Forecast to 2033 in real time.

  • Access a live Asthma and Severe Asthma Epidemiology Analysis and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.